CJC-1295 With DAC vs No DAC: What the Evidence Actually Shows
A clear comparison of CJC-1295 with DAC and the product commonly sold as CJC-1295 without DAC, including naming, half-life and evidence gaps.
Executive Summary
CJC-1295 with DAC and the material sold as “CJC-1295 no DAC” are not simply two strengths of the same product. The DAC form contains an albumin-binding modification that produces multi-day exposure. No-DAC usually refers to Modified GRF (1-29), a short-acting GHRH analogue. The strongest human pharmacokinetic evidence concerns the DAC form, and there is no direct clinical trial proving that one form produces better body-composition, recovery or anti-aging outcomes.
Why the Name Causes Confusion
The original CJC-1295 program used stabilizing substitutions in the active GHRH fragment and added a Drug Affinity Complex. In commercial peptide language, the stabilized fragment without the albumin-binding group is often called CJC-1295 no DAC. Scientific descriptions more commonly call it Modified GRF (1-29). A useful evidence page should state which molecule a study actually tested rather than assuming the names are interchangeable.
What DAC Does
DAC is an albumin-binding chemical group. Binding to serum albumin slows clearance and extends the period during which the compound can activate the GHRH receptor. In the published healthy-adult study, CJC-1295 produced sustained increases in GH and IGF-1 and had an estimated half-life measured in days.
What Is Known About No-DAC
Modified GRF (1-29) lacks the albumin-binding group and is expected to be cleared much more quickly. The short duration is consistent with the behavior of GHRH fragments, but online claims about exact duration, optimal schedules or superior “natural pulses” often exceed the direct clinical evidence. The dedicated human evidence base is much smaller than for the DAC compound.
Evidence Comparison
| Question | With DAC | No DAC / Modified GRF |
|---|---|---|
| Albumin-binding group | Present | Absent |
| Human pharmacokinetic study | Yes | Limited dedicated evidence |
| Exposure pattern | Multi-day | Short acting |
| Approved drug | No | No |
| Proven body-composition superiority | No | No |
Safety and Regulatory Context
Neither form is an FDA-approved drug. FDA materials identify concerns involving immunogenicity, peptide impurities, characterization and reported cardiovascular reactions for CJC-1295. Product identity matters because different salts, counterions and DAC status may affect characterization.
Key Insight
The DAC distinction is well supported at the level of molecular design and pharmacokinetics. Claims about which form is “better” for fat loss, muscle growth, sleep or recovery are not supported by direct comparative outcome trials.